FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES)
GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration (FDA) has granted a priority review for the company’s application seeking approval of Nucala (mepolizumab)…
Read More...
Read More...
